Pralsetinib (Gavreto) is a precision RET kinase inhibitor and has become an important treatment option for cancers associated with RET gene alterations. As a prescription medication, the purchase of pralsetinib must comply with strict medical standards and laws and regulations.

What Are the Purchase Channels for Pralsetinib (Gavreto)?

Overseas Purchase

Patients can choose to consult and purchase the drug at hospital pharmacies or licensed pharmacies in countries/regions where pralsetinib has been approved for marketing.

Due to factors such as regional price differences and exchange rate fluctuations, patients need to make a budget and plan in advance before purchasing.

Purchase via Medical Service Institutions

Patients can consult domestic overseas medical service institutions that cooperate with international pharmacies or pharmaceutical companies.

These institutions usually provide legal import channels as well as professional consulting and guidance services.

Notes on Purchasing Pralsetinib (Gavreto)

Mandatory Genetic Testing Before Medication Use

The decision to treat a patient with pralsetinib should be based on the presence of a RET gene fusion.

This indicates that prior to purchasing pralsetinib, patients must undergo RET gene fusion testing and confirm that they meet the indications before using the drug.

Strict Adherence to Dosage and Administration

The recommended dosage for adults and pediatric patients aged 12 years and older is 400 mg, taken orally once daily on an empty stomach.

The drug should be administered at least 2 hours before a meal or at least 1 hour after a meal.

Drug Interactions

Concomitant use with strong or moderate CYP3A inhibitors and/or P-gp inhibitors should be avoided during treatment. If co-administration is deemed necessary, the dosage of pralsetinib must be reduced accordingly.

Similarly, concomitant use with strong or moderate CYP3A inducers should be avoided. If co-administration is unavoidable, the dosage of pralsetinib needs to be increased.

Identification of Authentic Pralsetinib (Gavreto)

Check the Drug Packaging Features

Pralsetinib capsules are 100 mg, light blue, opaque hypromellose hard capsules, with "BLU-667" and "100mg" printed on the capsule shells.

Verify the Drug Approval Number

An important method is to verify the authenticity of the drug approval number through the official website of the National Medical Products Administration.

All pralsetinib legally sold in China must have a corresponding Import Drug Registration Certificate number.

Examine the Capsule Appearance

Genuine pralsetinib capsules should have an intact appearance, uniform color, and no signs of damage or discoloration.

Verification by Professional Medical Institutions

After purchasing the drug, patients can verify its authenticity through the medical institution that issued the prescription.